The short answer
Ginkgo deserves particular caution if you have epilepsy. A serious case involved phenytoin and several supplements, but does not prove that ginkgo alone lowered medication levels. Review the exact leaf product with your prescriber before use.
What this answer covers
Ginkgo leaf products with phenytoin; seed poisoning and multicomponent exposures do not establish the effect of every leaf extract.
- Supplement or preparation
- Ginkgo biloba
- Medication ingredient
- phenytoin
A serious report has important limits
A patient taking phenytoin, divalproex and multiple supplements had a fatal seizure and low postmortem drug concentrations. Ginkgo was one of the products. The report is a warning signal, but cannot isolate its effect or prove a specific absorption mechanism.
Enzyme studies do not give a reliable prediction
Human studies using other medicines as enzyme probes produced differing results, including no observed interaction and modest concentration changes. Those findings do not establish the amount of any phenytoin change in an individual patient.
Epilepsy is itself a reason for caution
The regulatory leaf monograph warns that ginkgo-associated additional seizures cannot be excluded in epilepsy. This concern is distinct from proving lower phenytoin levels. Seed-related toxicity should also not be presented as proof about every standardized leaf extract.
Discuss use before changing treatment
Bring all supplement labels to the treating clinician. There is no verified spacing interval that removes a possible effect on seizure control or drug metabolism. Continue prescribed phenytoin and seek assessment for new or worsening seizures.
Evidence and practical considerations
Side effects & toxicity
Ginkgo deserves particular caution if you have epilepsy. A serious case involved phenytoin and several supplements, but does not prove that ginkgo alone lowered medication levels. Review the exact leaf product with your prescriber before use.
- Exact scope
- Ginkgo leaf products with phenytoin; seed poisoning and multicomponent exposures do not establish the effect of every leaf extract. with Oral phenytoin; free-acid and sodium-salt formulations are explicitly distinguished.
- Medication form and route
- oral
What remains uncertain
- No universal risk rate or dose interval is established. Specific original-source limitations and access status are documented.
Factors that may matter: Exact preparation and amount; Medication formulation and drug levels; Seizure history and other treatments.
Read the supporting source summaries
Source 1: Current U.S. regulatory labeling
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed oral phenytoin for supported seizure indications.
Labels name folic acid and St John’s wort as possible causes of lower phenytoin levels. Calcium-carbonate and magnesium-hydroxide antacids should not be taken simultaneously. Abrupt withdrawal can worsen seizures.
How this applies: Exact medication precautions with the formulation bridge explicitly retained.
A generic mineral is not every antacid salt. Free-acid and sodium formulations have different drug content; oral absorption findings do not apply to intravenous administration.
Source 2: Original clinical case report
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: A55-year-old man treated with phenytoin and divalproex.
A fatal breakthrough seizure was reported; postmortem concentrations of both seizure medicines were low.
How this applies: A serious precautionary signal, not proof of reduced phenytoin absorption or an interaction frequency.
Multiple co-exposures and postmortem measurements prevent attribution to ginkgo alone. Suggested enzyme mechanisms were not directly proved.
Source 3: Original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Healthy volunteers in two open-label crossover studies.
No in-vivo change in the measured probe pharmacokinetics despite laboratory inhibition.
How this applies: Shows why laboratory enzyme effects cannot be translated directly to this drug.
Probe medicines are not phenytoin; product-specific results cannot establish every extract’s effect.
Source 4: Original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Ten healthy men.
Tolbutamide exposure fell modestly while midazolam exposure increased.
How this applies: Mixed probe results do not establish the size or mechanism of a phenytoin interaction.
Small product-specific study without phenytoin; pathways and dosing differ.
Source 5: Regulatory herbal monograph
ema.europa.eu · Source check Sep 10, 2026
Population: People using covered ginkgo leaf preparations, including those with epilepsy.
Warns that further seizures promoted by ginkgo preparations cannot be excluded in epilepsy.
How this applies: Supports prescriber review without assigning seed-toxin mechanisms to all leaf extracts.
General epilepsy precaution, not a quantified phenytoin pharmacokinetic study.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Initial source-checked research draft with exact formulation limits, contrary evidence and source-access details. Clinical review not recorded. | |
| Research summary published |
Article revision: 240089fd18e182d9
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.